RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Pacira Biosciences Stock

Pacira Biosciences P/E 2024

Pacira Biosciences P/E

11.23

Ticker

PCRX

ISIN

US6951271005

WKN

A1H68T

As of Sep 29, 2024, Pacira Biosciences's P/E ratio was 11.23, a -76.17% change from the 47.13 P/E ratio recorded in the previous year.

The Pacira Biosciences P/E history

Pacira Biosciences Aktienanalyse

What does Pacira Biosciences do?

Pacira Biosciences Inc. is an international pharmaceutical company specializing in the development and manufacture of innovative drugs for use in anesthesia, pain management, and oncology. The company was founded in 2007 and is headquartered in Parsippany, New Jersey. Pacira Biosciences' success story began with the development of EXPAREL, a long-acting painkiller based on liposome technology. EXPAREL was the first product approved by the US Food and Drug Administration (FDA) for local infiltration to relieve pain after surgery. Since then, the company has expanded its portfolio and now offers products for use in oncology and other areas of medicine. Pacira Biosciences' business model is based on the manufacture and sale of high-quality, innovative drugs both in the US and internationally. Product development is done in close collaboration with doctors and patients to ensure that patient needs are met and medical requirements are fulfilled. The company operates in three main divisions: anesthesia, pain management, and oncology. In the anesthesia division, Pacira Biosciences offers the product EXPAREL, which is used for local infiltration into the surgical wound to relieve pain after surgery. EXPAREL is a liposomal, slow-release painkiller that enables patients to recover without pain and minimizes the risk of opioid dependence. In the pain management division, Pacira Biosciences has developed the products bupivacaine and meloxicam, which are used in the treatment of acute and chronic pain. These products provide a safe and effective alternative to opioids for pain management. In the oncology division, the company has introduced the product ONIVYDE, which is used for the treatment of patients with metastatic pancreatic cancer. ONIVYDE was developed in collaboration with the FDA and has proven to be effective in combating cancer. In addition to offering products, Pacira Biosciences works closely with doctors, hospitals, and government agencies to ensure that the products are used safely and effectively. The company also conducts extensive research and development activities to develop new products and improve existing ones. In conclusion, Pacira Biosciences Inc. is a leading international company specializing in innovative pharmaceuticals in the fields of anesthesia, pain management, and oncology. The company is actively working on developing new innovative products and offering doctors and patients a safe and effective alternative to traditional pain medications. With its strong commitment to the healthcare industry, Expard will continue to advance the development of new and therapeutic agents to better assist patients. Answer: Pacira Biosciences Inc. is an international pharmaceutical company specializing in the development and manufacture of innovative drugs for anesthesia, pain management, and oncology. They are known for their product EXPAREL, a long-acting painkiller approved by the FDA for local infiltration after surgery. The company operates in three divisions and works closely with healthcare professionals and government agencies to ensure safe and effective use of their products. They are committed to advancing healthcare through research and development. Pacira Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Pacira Biosciences's P/E Ratio

The Price to Earnings (P/E) Ratio of Pacira Biosciences is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Pacira Biosciences's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Pacira Biosciences is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Pacira Biosciences’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Pacira Biosciences stock

What is the price-to-earnings ratio of Pacira Biosciences?

The price-earnings ratio of Pacira Biosciences is currently 11.23.

How has the price-earnings ratio of Pacira Biosciences changed compared to last year?

The price-to-earnings ratio of Pacira Biosciences has increased by -76.17% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Pacira Biosciences high compared to other companies?

Yes, the price-to-earnings ratio of Pacira Biosciences is high compared to other companies.

How does an increase in the price-earnings ratio of Pacira Biosciences affect the company?

An increase in the price-earnings ratio of Pacira Biosciences would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Pacira Biosciences affect the company?

A decrease in the price-earnings ratio of Pacira Biosciences would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Pacira Biosciences?

Some factors that influence the price-earnings ratio of Pacira Biosciences are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Pacira Biosciences pay?

Over the past 12 months, Pacira Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pacira Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Pacira Biosciences?

The current dividend yield of Pacira Biosciences is .

When does Pacira Biosciences pay dividends?

Pacira Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pacira Biosciences?

Pacira Biosciences paid dividends every year for the past 0 years.

What is the dividend of Pacira Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pacira Biosciences located?

Pacira Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pacira Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pacira Biosciences from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Pacira Biosciences pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Pacira Biosciences in the year 2023?

In the year 2023, Pacira Biosciences distributed 0 USD as dividends.

In which currency does Pacira Biosciences pay out the dividend?

The dividends of Pacira Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Pacira Biosciences

Our stock analysis for Pacira Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pacira Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.